156 related articles for article (PubMed ID: 33441852)
1. Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs.
Leira Y; Domínguez C; Ameijeira P; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; Blanco J; Leira R
Sci Rep; 2021 Jan; 11(1):1092. PubMed ID: 33441852
[TBL] [Abstract][Full Text] [Related]
2. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
[TBL] [Abstract][Full Text] [Related]
4. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
5. Periodontal inflammation is related to increased serum calcitonin gene-related peptide levels in patients with chronic migraine.
Leira Y; Ameijeira P; Domínguez C; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; D'Aiuto F; Leira R; Blanco J
J Periodontol; 2019 Oct; 90(10):1088-1095. PubMed ID: 31070784
[TBL] [Abstract][Full Text] [Related]
6. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
[TBL] [Abstract][Full Text] [Related]
7. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
[TBL] [Abstract][Full Text] [Related]
8. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
9. [Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine].
Pagola I; Esteve-Belloch P; Palma JA; Luquin MR; Riverol M; Martinez-Vila E; Irimia P
Rev Neurol; 2014 Mar; 58(6):241-6. PubMed ID: 24610690
[TBL] [Abstract][Full Text] [Related]
10. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
[TBL] [Abstract][Full Text] [Related]
11. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
Quintas S; García-Azorín D; Heredia P; Talavera B; Gago-Veiga AB; Guerrero ÁL
Pain Med; 2019 Sep; 20(9):1815-1821. PubMed ID: 30657951
[TBL] [Abstract][Full Text] [Related]
12. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.
Moreno-Mayordomo R; Ruiz M; Pascual J; Gallego de la Sacristana M; Vidriales I; Sobrado M; Cernuda-Morollon E; Gago-Veiga AB; Garcia-Azorin D; Telleria JJ; Guerrero AL
J Headache Pain; 2019 Apr; 20(1):39. PubMed ID: 31014225
[TBL] [Abstract][Full Text] [Related]
13. Experience with botulinum toxin in chronic migraine.
Castrillo Sanz A; Morollón Sánchez-Mateos N; Simonet Hernández C; Fernández Rodríguez B; Cerdán Santacruz D; Mendoza Rodríguez A; Rodríguez Sanz MF; Tabernero García C; Guerrero Becerra P; Ferrero Ros M; Duate García-Luis J
Neurologia (Engl Ed); 2018 Oct; 33(8):499-504. PubMed ID: 27776965
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
Cernuda-Morollón E; Ramón C; Larrosa D; Alvarez R; Riesco N; Pascual J
Cephalalgia; 2015 Sep; 35(10):864-8. PubMed ID: 25431141
[TBL] [Abstract][Full Text] [Related]
15. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers.
Dahri M; Tarighat-Esfanjani A; Asghari-Jafarabadi M; Hashemilar M
Nutr Neurosci; 2019 Sep; 22(9):607-615. PubMed ID: 29298622
[No Abstract] [Full Text] [Related]
16. Is the severity of periodontitis related to gingival crevicular fluid and serum high-sensitivity C-reactive protein concentrations?
Baser U; Oztekin G; Ademoglu E; Isik G; Yalcin F
Clin Lab; 2014; 60(10):1653-8. PubMed ID: 25651710
[TBL] [Abstract][Full Text] [Related]
17. [OnabotulinumtoxinA in chronic migraine: from the theory of clinical trials to clinical practice].
Leira R
Rev Neurol; 2014 Mar; 58 Suppl 2():S3-11. PubMed ID: 24687883
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial.
Ghorbani Z; Togha M; Rafiee P; Ahmadi ZS; Rasekh Magham R; Djalali M; Shahemi S; Martami F; Zareei M; Razeghi Jahromi S; Ariyanfar S; Mahmoudi M
Neurol Sci; 2020 May; 41(5):1183-1192. PubMed ID: 31897949
[TBL] [Abstract][Full Text] [Related]
19. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
Gonzalez-Martinez A; Rodríguez Vázquez E; de la Red Gallego H; García-Azorín D; Gallego de La Sacristana M; Guerrero Peral ÁL; Gago-Veiga AB
Headache; 2020 Jan; 60(1):153-161. PubMed ID: 31691958
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
